Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Analyst Who Called XRP Rally to New All-High Says Massive Move Is Coming. Here’s why

Analyst Who Called XRP Rally to New All-High Says Massive Move Is Coming. Here’s why

TimesTabloidTimesTabloid2026/10/25 17:03

Crypto analyst JD (@jaydee_757) has shared a detailed technical assessment of XRP on the weekly chart, identifying a significant structural shift that could signal the beginning of a new bullish phase. The assessment arrives after an extended period of price deterioration that began following XRP’s peak earlier in the bull cycle.

Since XRP hit its all-time high of $3.65 in July 2025, it has produced a consistent pattern of lower highs and lower lows on the weekly timeframe. This structure defined a clear downtrend, with each attempted recovery falling short of the previous high.

It also put the asset within a falling wedge pattern. JD tracked these levels carefully across the chart, labeling each LH and LL as the trend developed and intensified through late 2025.

After months of LH & LL, XRP finally BROKE OUT and created a HH! 🔥

Now watching for a HL to confirm bullish structure!

⚠️ Weekly RSI nearing a BEARISH CROSS while hitting our GREY BOX posted on Patreon again!🎯

The Breakout and What Followed

The chart shows that XRP eventually broke out of its descending channel. After a brief dip below $1, XRP experienced a sharp upward move in August, breaking out of the falling wedge pattern. Following that breakout, the price produced what JD labels a higher high.

That development carries significance because it breaks the sequence of lower highs that had defined the trend. The current focus is on whether a higher low forms next. JD is watching for confirmation that the structure has genuinely reversed.

A confirmed higher low would establish the early stages of an uptrend pattern, consistent with the diagram JD included on the chart showing the sequence of HL, HH, HL, HH that defines a bullish trend.

RSI Adds a Layer of Caution

JD flags a potential concern on the weekly RSI. The indicator is approaching a bearish cross. He references two prior instances where this signal appeared. The first produced a 63% decline. The second produced a 27% drop.

The current setup is approaching that same configuration. He marks it with a circled RSI reading near the October 2026 area on the chart. At the time of his analysis, XRP traded at $1.2839. The grey box sits just below current levels, near the 0.618 and 0.786 Fibonacci levels marked on the chart.

The Long-Range Projection

Beyond the near-term structure, JD includes a projection extending toward a 2028 top. A white line points upward, exceeding the $3.80 level on the chart. This suggests JD sees that level as a longer-term target if the bullish structure confirms and holds. JD states he will “TAKE MASSIVE PROFITS” at targets outlined on his monthly chart.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.